We can support you in obtaining formal, or informal payer insights to your clinical trial designs to ensure they enhance your HTA submission.
Providing HTA and European regulators (EMA) feedback on your planned clinical trial program.
Understanding what is required to achieve a positive NICE single technology appraisal (STA) is key to your Pharmaceutical Launch strategy.
The Office of Market Access can provide guidance on positioning, uptake and adoption of your treatment in the NHS.
Country scientific advice can provide detail, targeted guidance on critical pricing and market access topics.
The Innovative Licensing and Access Pathway ( ILAP ) aims to accelerate the time to market for products to help patient access to medicines.
Payer advisory boards are essential to understand payer evidence needs on a more informal basis.
Payer insights can be a rapid, efficient way to gain payer feedback to support your decision making.